Laparoscopic surgery for colon cancer with specimen extraction through the rectum
Laparoscopic Right Hemicolectomy With Transrectal Specimen Extraction for Colon Cancer
This study is testing a new way to remove right colon cancer using minimally invasive surgery and a technique that takes the specimen out through the rectum to see if it leads to fewer complications and better recovery for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 37 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | National Cancer Center, China Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06362902 on ClinicalTrials.gov |
What this trial studies
This study investigates the surgical outcomes of laparoscopic right hemicolectomy combined with transrectal specimen extraction for patients with right colon cancer. It is a prospective single-arm clinical study involving 37 patients, aiming to assess postoperative complications and other factors such as operating time and quality of life. The primary hypothesis is that this innovative approach, known as natural orifice specimen extraction surgery (NOSES), can lead to fewer complications compared to traditional methods.
Who should consider this trial
Good fit: Ideal candidates are patients with biopsy-proven colon carcinoma located in the cecum, ascending colon, or colonic hepatic flexure, with a tumor diameter of 5 cm or less.
Not a fit: Patients with complete intestinal obstruction, significant organ dysfunction, or other severe medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved surgical outcomes and reduced complications for patients undergoing surgery for right colon cancer.
How similar studies have performed: While this approach is innovative, similar studies exploring natural orifice specimen extraction have shown promising results, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Biopsy proven colon carcinoma; 2. Imaging diagnosis of T1-3 colon cancer; 3. The tumor located in the cecum, ascending colon, or colonic hepatic flexure; 4. Maximal tumor diameter ≤5 cm; 5. Body mass index (BMI) ≤30 kg/m2; 6. Written informed consent; Exclusion Criteria: 1. Complete intestinal obstruction; 2. Hepatitis activity and peripheral neuropathy (such as peripheral neuritis, pseudo meningitis, motor neuritis, and sensory impairment); 3. Significant organ dysfunction or other significant diseases, including clinically relevant coronary artery disease, cardiovascular disease, or myocardial infarction within the 12 months before enrollment; severe neurological or psychiatric history; severe infection; active disseminated intravascular coagulation; 4. Pregnancy or breastfeeding; 5. Alcohol abuse or drug addiction; 6. Concurrent uncontrolled medical condition;
Where this trial is running
Beijing, Beijing
- National Cancer Center — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Zheng Xu, M.D.
- Email: 1206164395@qq.com
- Phone: +8618800157037
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.